Delving into the Latest Updates on MK-1708 with Synapse

Overview

Basic Info

Drug Type

Unknown

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseOther Diseases

Active Indication

Alzheimer DiseaseAmyotrophic Lateral Sclerosis

Inactive Indication-

Originator Organization

Merck Sharp & Dohme LLC

Active Organization

Merck Sharp & Dohme LLC

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The purpose of this study is to learn about the safety of MK-1708, and how well elderly people tolerate it. The study will also measure what happens to MK-1708 in a healthy elderly person's body over time (pharmacokinetic or PK study). Researchers will learn if at least 1 dose level of MK-1708 will be safe, well-tolerated, and will be above a certain level in people's blood after 24 hours.

Start Date04 Nov 2024

Sponsor / Collaborator

Merck Sharp & Dohme LLC

JPRN-jRCT2071240035

/ SuspendedPhase 1IIT

Single and Multiple Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-1708 in Healthy Japanese Participants

Start Date04 Oct 2024

Sponsor / Collaborator-

NCT06586606

/ CompletedPhase 1

A Two-Period Study to Evaluate the Effects of Multiple Oral Doses of Itraconazole on the Single Dose PK of MK-1708 in Healthy Participants

The goal of the study is to see what happens to levels of MK-1708 a person's body over time. Researchers will compare what happens to MK-1708 in the body when it is given with or without a medicine called itraconazole.

Start Date03 Oct 2024

Sponsor / Collaborator

Merck Sharp & Dohme LLC

100 Clinical Results associated with MK-1708

Login to view more data

100 Translational Medicine associated with MK-1708

Login to view more data

100 Patents (Medical) associated with MK-1708

Login to view more data

100 Deals associated with MK-1708

Login to view more data